Clinical Trials


Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

This study has been completed
Bristol-Myers Squibb

Information provided by (Responsible Party)
Bristol-Myers Squibb Identifier

First received: October 15, 2015
Last updated: April 29, 2016
Last Verified: February 2016
History of Changes


The purpose of the study is to study the effects of BMS-955176 on the single-dose PK parameters of probe substrates caffeine, metoprolol, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin

Condition Intervention Phase

Drug : Cocktail of CYP (cytochrome P450) and transporter probe substrates
Drug : BMS-955176
Drug : BMS-955176 plus the cocktail of CYP and transporter probe substrates
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures

  • Cmax (maximum observed concentration) [ Time Frame: Days 1 to 18 ]
  • AUC(0-T), area under the concentration-time curve from time zero to the time of the last quantifiable concentration [ Time Frame: Days 1 to 18 ]
  • AUC(INF), area under the concentration-time curve from time zero extrapolated to infinite time [ Time Frame: Days 1 to 18 ]

Enrollment: 20
Study Start Date: November 2015
Study Completion Date: December 2015
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Single sequence, 3-period DDI (drug-drug interaction)

Drug: Cocktail of CYP (cytochrome P450) and transporter probe substrates
Drug: BMS-955176
Drug: BMS-955176 plus the cocktail of CYP and transporter probe substrates


Ages Eligible for Study: 18 Years to 50 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  


Inclusion Criteria:

    1. Written Informed Consent
    2. Healthy male and female (not of childbearing potential) subjects as determined by medical history, surgical history, physical examination, vital signs, ECGs, and clinical laboratory determinations
    3. Body mass index (BMI) of 18.0 kg/m2 to 32.0 kg/m2, inclusive, at screening and Day 1. BMI = weight (kg)/[height(m)]
    4. Women must have documented proof that they are not of childbearing potential (eg, surgically sterile, postmenopausal with a documented follicle-stimulating hormone (FSH) > 40 mIU/mL) and should not be breast feeding
    5. Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with BMS-955176 in addition to a post-treatment completion period

Exclusion Criteria:
    1. Any significant acute or chronic medical illness
    2. Use of tobacco, excessive alcohol
    3. Medical history indicative of an increased risk of a cardiac arrhythmia or cardiac disease and history of asthma, bronchospasm, sleep apnea, rhabdomyolysis, a bleeding disorder, a major depressive disorder within the past 6 months, peptic ulcer or significant GI bleed, Raynaud's disease, or any gastrointestinal surgery that could impact upon the absorption of study drug
    4. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population
    5. History of allergy to BMS-955176, digoxin (or any member of the digitalis glycosides
    class of drugs), caffeine, metoprolol, montelukast, flurbiprofen, omeprazole, midazolam, or pravastatin, or to any related compounds

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02578277


United States, Texas
Ppd Development, Lp
Austin, Texas, United States, 78744

Sponsors and Collaborators

Bristol-Myers Squibb
More Information

More Information

Responsible Party: Bristol-Myers Squibb Identifier: NCT02578277   History of Changes  
Other Study ID Numbers: AI468-063  
Study First Received: October 15, 2015  
Last Updated: April 29, 2016 processed this data on December 15, 2017
This information is provided by